Want to see IN:THEMISMED full AI Analyst Report?
THEMISMED Stock Chart & Stats
₹102.50
₹17.25(6.68%)
At close: 4:00 PM EST
₹102.50
₹17.25(6.68%)
Day’s Range― - ―
52-Week Range₹65.00 - ₹147.99
Previous CloseN/A
Volume256.77K
Average Volume (3M)6.87K
Market Cap
₹10.75B
Enterprise Value₹10.36B
Total Cash (Recent Filing)₹91.50M
Total Debt (Recent Filing)₹1.00B
Price to Earnings (P/E)888.8
Beta1.60
Next Earnings
Aug 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.48%
Share Statistics
EPS (TTM)0.13
Shares Outstanding92,100,120
10 Day Avg. Volume6,301
30 Day Avg. Volume6,868
Financial Highlights & Ratios
PEG Ratio-5.72
Price to Book (P/B)1.58
Price to Sales (P/S)1.84
P/FCF Ratio-37.64
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Manageable LeverageDebt-to-equity near 0.25 provides durable financial flexibility to fund working capital, capex or R&D without immediate distress. Over a 2–6 month horizon this balance-sheet capacity helps absorb margin volatility, pursue strategic initiatives and avoid forced recapitalization.
Recent Top-line ReboundA 33.9% revenue rebound indicates meaningful demand recovery or improved commercial execution. Sustained revenue growth creates scale to absorb fixed costs, enables reinvestment in product and market expansion, and provides a foundation for structural margin recovery if cost and mix issues are addressed.
Integrated API And Formulation ModelOwning both API and finished-dosage capabilities with domestic and export reach creates vertical integration and geographic diversification. This structural model can improve gross margin capture, reduce supply-chain risk, and sustain revenues across cycles by serving multiple customer types and markets.
Bears Say
Severe Margin CompressionA collapse in gross margin and negative EBIT signal deep profitability stress that reduces the firm's ability to generate sustainable earnings. Over months this undermines free cash generation, constrains reinvestment, and suggests structural pricing, input-cost or product-mix issues that must be corrected to restore durable profitability.
Negative Operating And Free Cash FlowConversion to negative operating and free cash flow reverses prior cash-generation trends and raises persistent liquidity risk. Without sustained cash inflows, the company may need external financing for working capital and capex, increasing funding costs and execution risk over the next several quarters.
Collapse In Returns On EquityROE falling to near zero indicates the business is no longer converting capital into meaningful shareholder returns. This decline reflects structural inefficiencies in margins or asset utilization and weakens long-term investor confidence and capacity to attract capital without operational turnaround.
Themis Medicare Limited News
THEMISMED FAQ
What was Themis Medicare Limited’s price range in the past 12 months?
Themis Medicare Limited lowest stock price was ₹65.00 and its highest was ₹147.99 in the past 12 months.
What is Themis Medicare Limited’s market cap?
Themis Medicare Limited’s market cap is ₹10.75B.
When is Themis Medicare Limited’s upcoming earnings report date?
Themis Medicare Limited’s upcoming earnings report date is Aug 07, 2026 which is in 21 days.
How were Themis Medicare Limited’s earnings last quarter?
Themis Medicare Limited released its earnings results on May 28, 2026. The company reported ₹0.96 earnings per share for the quarter, beating the consensus estimate of N/A by ₹0.96.
Is Themis Medicare Limited overvalued?
According to Wall Street analysts Themis Medicare Limited’s price is currently Overvalued.
Does Themis Medicare Limited pay dividends?
Themis Medicare Limited pays a Annually dividend of ₹0.5 which represents an annual dividend yield of 0.48%. See more information on Themis Medicare Limited dividends here
What is Themis Medicare Limited’s EPS estimate?
Themis Medicare Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Themis Medicare Limited have?
Themis Medicare Limited has 92,100,120 shares outstanding.
What happened to Themis Medicare Limited’s price movement after its last earnings report?
Themis Medicare Limited reported an EPS of ₹0.96 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Themis Medicare Limited?
Currently, no hedge funds are holding shares in IN:THEMISMED
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Themis Medicare Limited
Themis Medicare Limited, along with its affiliated entities, is a pharmaceutical company that produces and supplies medicinal goods for both the Indian and international markets. Its product portfolio encompasses active pharmaceutical ingredients (APIs) and various drug formulations, designed for application across diverse medical domains such as anti-infectious conditions, malaria, tuberculosis, cardiovascular issues, health and wellness, cancer, eye diseases, and pain relief. Founded in 1969, the company operated under the name Themis Chemicals until 2001, when it officially changed to Themis Medicare Limited. The company's primary operations are directed from its Mumbai, India headquarters.
Technical Analysis
Ind-Swift Laboratories Ltd.
―
Jagsonpal Pharmaceuticals Ltd.
―
Venus Remedies Limited
―
Wanbury Limited
―
Zim Laboratories Ltd.
―